1. Introduction {#sec1}
===============

Damage to the cellular DNA can transiently inhibit the activity of RNA polymerase II at a time when DNA damage response (DDR) proteins and DNA repair proteins are critically needed \[[@B1]\]. As transcription is reduced, there is increased need to regulate the production of proteins from the pre-existing pool of mRNAs. Two main posttranscriptional mechanisms control protein expression following genotoxic damage: mRNA turnover and translational regulation \[[@B2], [@B3]\]. These two sets of events are potently influenced by RNA-binding proteins (RBPs) and noncoding RNAs (primarily microRNAs), which interact with mRNAs and modulate their half-lives and translation rates \[[@B4]--[@B6]\].

During the DDR, several RBPs showing altered levels or subcellular localization have been implicated in controlling gene expression. For example, many RBPs that control RNA metabolism showed altered expression in response to ionizing radiation (IR) and ultraviolet radiation (UV) \[[@B7]\]; in another study, several members of the heterogeneous ribonuclear protein (hnRNP) family were found to participate in the response to IR \[[@B8]\]. Specific RBPs have also been shown to participate in different types of DDR; for example, the RBPs AU-binding factor 1 (AUF1) and T cell-restricted intracellular antigen-related protein (TIAR) controlled the expression of the growth arrest- and DNA damage-inducible (gadd)45a protein in response to alkylating DNA damage \[[@B9]\], the RBPs nucleolin and nucleophosmin participated in the cellular responses to IR and UV \[[@B10]\], and the RBP Sam68 modulated alternative splicing following DNA damage \[[@B11]\]. One of the best characterized RBPs that control expression of DDR genes, HuR, is the subject of this review.

2. Stress-Response Protein HuR {#sec2}
==============================

HuR is the ubiquitous member of the embryonic lethal abnormal vision (ELAV)/Hu family of RBPs, which also contains the primarily neuronal members HuB, HuC, and HuD \[[@B12]\]. Although HuR is predominantly nuclear, its translocation to the cytoplasm is linked to its ability to stabilize target mRNAs and/or modulate their translation \[[@B13], [@B14]\]. The 326-aa long HuR binds target mRNAs through its three RNA recognition motifs (RRMs); located between RRM2 and RRM3 is a hinge region that encompasses a nucleocytoplasmic shuttling sequence (HNS, spanning residues 205--237 \[[@B15]\]) ([Figure 1](#fig1){ref-type="fig"}). The nuclear export of HuR is mediated by its association with transportin 1 (Trn1) and Trn2 \[[@B16]\] and with nuclear ligands pp32 and APRIL, which contain nuclear export signals that are recognized by the export receptor CRM1 \[[@B17], [@B18]\].

HuR target mRNAs encode many proteins implicated in the cellular response to DNA damage, including tumor suppressors (p53, pVHL), cyclins (A, B1, and D1), proto-oncogenes (c-fos, c-myc), growth factors (VEGF), cytokines (TGF-*β*, TNF-*α*), cyclin-dependent kinase (cdk) inhibitors (p21, p27), antiapoptotic factors \[prothymosin *α* (ProT*α*), Bcl-2, and Mcl-1\], and signaling molecules like the mitogen-activated protein (MAP) kinase phosphatase MKP-1 \[[@B19]--[@B30]\] ([Table 1](#tab1){ref-type="table"}); most of these transcripts contain one or several copies of a U-rich RNA signature motif \[[@B31]\]. Given the functions of the proteins encoded by HuR-regulated mRNAs, HuR has been implicated in processes such as carcinogenesis, proliferation, immune function, differentiation, and responsiveness to oxidative and genotoxic damage \[[@B14], [@B26], [@B32]--[@B38]\].

With a few exceptions \[[@B38], [@B39]\], acute changes in HuR function do not involve changes in protein abundance but rely instead on two regulatory steps: (1) the subcellular localization of HuR and (2) the interaction of HuR with target mRNAs. In response to DNA-damaging stresses, the past few years have uncovered a signaling pathway that jointly affects both of these processes, HuR\'s subcellular distribution and its interaction with target transcripts. DNA damage is recognized by sensor proteins, such as the Rad9-Rad1-Hus1 complex (also termed "9-1-1 complex") that recognizes certain types of DNA damage and is mediated by proteins such as those that comprise the Mre11-Rad50-Nbs1 complex (MRN), which recruits the transducer protein DNA damage-activated ataxia telangiectasia mutated (ATM) to sites of DNA damage \[[@B40]\]. The transducer proteins include the kinases ATM and ATM- and Rad3-related (ATR); ATM/ATR phosphorylates and thereby activates the checkpoint kinases Chk1 and Chk2, which control HuR cytoplasmic abundance and RNA binding, respectively. ATM is primarily activated by double-strand breaks in DNA, such as those caused by IR \[[@B41]\] while ATR is activated in response to other damaging agents, including UV, alkylating agents, and chemical inhibitors of DNA replication \[[@B42], [@B43]\], but there is extensive evidence that both kinases work in tandem \[[@B44]\]. As these kinases are essential for genomic integrity, deficiencies in ATM/ATR and other components of DNA damage checkpoints cause debilitating diseases such as ataxia telangiectasia, Fanconi\'s anemia, and Seckel syndrome, thereby contributing to premature aging and carcinogenesis \[[@B45], [@B46]\]. Given that HuR target transcripts encode proteins implicated in the DDR, HuR control by ATM/ATR is rising as a major gene regulatory paradigm in the pathophysiology of DNA damage ([Figure 2](#fig2){ref-type="fig"}). Consequently, even in the presence of normal HuR levels in the cell, HuR\'s ability to regulate DDR gene expression posttranscriptionally is impaired in cells with aberrant ATM/ATR signaling.

3. Regulation of HuR by ATM/ATR → Chk1 ⊣ Cdk1 {#sec3}
=============================================

During DDR such as that resulting from exposure to UV, oxidants, or IR, Chk1 is phosphorylated by ATM/ATR at serine (S)317 and S345 \[[@B47]\]. Chk1 plays a pivotal role in the regulation of the cell division cycle by phosphorylating proteins such as the cyclin-dependent kinase 1 (Cdk1, also named Cdc2). ATM/ATR → Chk1 signaling leads to the inactivation of a dual-specificity phosphatase, Cdc25, which consists of three members (A, B, and C). Chk1 phosphorylates Cdc25A at S76, a modification that triggers the degradation of Cdc25A via SCF*β*-TRCP-mediated ubiquitination \[[@B48]\]. Chk1 also associates with Cdc25B and Cdc25C and inactivates these phosphatases through phosphorylation at S309/323 and S216, respectively, in turn causing their nuclear exclusion through association with 14-3-3 \[[@B49]\]. Cdk1 is fully activated in two steps: by phosphorylation at threonine (T)161 via the kinase Cdk7 and by dephosphorylation of phosphor- (p-) thyrosine (Y)15 via the phosphatase Cdc25. Thus, by inhibiting Cdc25, ATM/ATR → Chk1 inactivates Cdk1. Additionally, Chk1 activates the kinase Wee1, which is responsible for the inhibitory phosphorylation of Cdk1 at Y15 \[[@B50]\]. As recently reported, during mitosis Cdk1 phosphorylates Chk1 at S286 and S301; the mitotic phosphorylation of Chk1 is accompanied by the translocation of Chk1 to the cytoplasm \[[@B51]\]. Phosphorylation of Chk1 resulting in its removal from chromatin has been shown to modify cytoplasmic substrates and plays a role at the centrosome during cell division \[[@B52]\].

The cellular DDR dynamically regulates the subcellular presence of HuR. Although predominantly nuclear, exposure to UV or oxidants triggers the accumulation of HuR in the cytoplasm \[[@B20], [@B24], [@B53]\], where it modulates the stability and/or translation of numerous target mRNAs, as explained above. We recently reported that HuR was a direct substrate for Cdk1, which phosphorylated HuR at S202 \[[@B29]\]. HuR subcellular localization during the cell division cycle followed fluctuations in Cdk1 activity \[[@B29]\]. The reduction in Cdk1 activity that followed UV irradiation of HeLa cells resulted in the loss of HuR phosphorylation at S202, which in turn promoted the cytoplasmic accumulation of HuR. HuR translocation following Cdk1 inhibition was linked to the nuclear interaction of p-HuR(S202) and 14-3-3 \[[@B29]\]. Inhibition or silencing of Cdk1 enhanced the cytoplasmic level of HuR and increased its interaction with target mRNAs, including those that encode anti-apoptotic proteins like Bcl-2, Mcl-1, and prothymosin-*α*; therefore, lowering Cdk1 also diminished the proapoptotic influence of etoposide or staurosporine. Given that DNA damage triggered by many agents reduces Cdk1 activity and increases the cytoplasmic presence of HuR, it is likely that the ATM/ATR → Chk1 ⊣ Cdk1 pathway is broadly responsible for controlling the cytoplasmic levels of HuR after different types of DDR.

Other DNA damage-activated pathways also affect HuR localization through Cdk1. Activation of the MAP kinase (MAPK) p38 by DNA damage phosphorylates Cdc25B and thus triggers it for degradation. In this manner, p38 affects Cdk1 levels through its influence on Cdc25B abundance. DNA damage induces the cleavage of PKC*δ* and generates a constitutively active catalytic fragment termed PKC*δ*-cat. PKC*δ*-cat can also phosphorylate Cdk1 at Y15, thereby inactivating Cdk1 and inducing G2/M arrest. Moreover, PKC*δ* can phosphorylate directly HuR at S221 and S318 (see below), triggering the cytoplasmic translocation of HuR \[[@B54]\]. Overall, DNA damage inactivates Cdk1, which increases cytoplasmic HuR level and thus enhances mRNA stability and translation of DNA damage response proteins.

4. Regulation of HuR by ATM/ATR → Chk2 {#sec4}
======================================

One of the main roles of the ATM/ATR → Chk2 pathway is to induce cell cycle arrest, allowing cells to repair damaged DNA \[[@B55]\]; see \[[@B56]\] for a recent review on Chk2 and Chk1. Activated Chk2 phosphorylates downstream effectors such as p53, BRCA1, and Cdc25 and Cdc25A, which are involved in cellular processes such as apoptosis, DNA repair, and growth arrest \[[@B57]\].

Exposure of human diploid fibroblasts to genotoxic doses of hydrogen peroxide (H~2~O~2~) activated Chk2, which in turn phosphorylated HuR \[[@B27]\]. HuR phosphorylation by Chk2 triggered the dissociation of the mRNA encoding the longevity and stress-response protein SIRT1 from HuR ribonucleoprotein (RNP) complexes; this dissociation rendered the *SIRT1* mRNA unstable and triggered a decrease in the abundance of *SIRT1* mRNA and protein. Three putative Chk2 phosphorylation sites were identified: HuR residues S88, S100, and T118. In human diploid fibroblasts, mutating S100 to a nonphosphorylatable residue (S100A) promoted the continued association of *SIRT1* mRNA with HuR after oxidative damage, indicating that phosphorylation at residue S100 (located between RRM1 and RRM2) was critical for dissociation of the mRNA \[[@B27]\]. A more stable target transcript, the *prothymosin *α** (*PTMA*) mRNA, also showed increased binding to HuR(S100A) compared to wild-type HuR following H~2~O~2~ treatment. Interestingly, mutation of T118 (located within RRM2) to a nonphosphorylatable site (T118A) generally showed reduced binding to all target mRNAs, suggesting that phosphorylation at T118 enhanced HuR binding to target mRNAs. Additional studies are needed to elucidate if other DNA-damaging agents also act upon Chk2 to phosphorylate HuR and how these modifications affect HuR function following genotoxic stress. Further work is also necessary to investigate how other HuR target mRNAs are regulated following HuR phosphorylation by Chk2.

Unexpectedly, HuR phosphorylation by Chk2 in response to heat shock helped to prevent its degradation in this stress paradigm \[[@B38]\]. Following heat shock, the nonphoshorylatable HuR mutants (S88A, S100A, and T118A) were more labile while HuR phosphomimic mutants (S88D, S100D, and T118D) were more resistant to degradation \[[@B38]\]. Although details of this process await further analysis, Chk2 phosphorylation of HuR appeared to block HuR proteolysis mediated by ubiquitination at HuR residue K182 \[[@B38]\]. Whether DNA damage also helps to increase HuR stability via Chk2-mediated phosphorylation also warrants careful consideration.

In addition, since Chk2 phosphorylates HuR, and Chk2 mutations influence Chk2 function, it is important to study in detail the influence of Chk2 upon HuR function on target mRNAs, just as was done for*SIRT1* mRNA \[[@B27]\]. Chk2 was found to be mutated in the Li-Fraumeni cancer syndrome and in cancer \[[@B58], [@B59]\]; these mutations modified Chk2\'s ability to interact with substrates, Chk2 kinase activity, and Chk2 subcellular localization \[[@B55], [@B60]\]. How the role of HuR in gene expression is affected in Chk2 mutant cells remains unclear and will be an important aim of future studies.

5. Other HuR Kinases Regulated by DNA Damage {#sec5}
============================================

Genotoxic damage also activates additional kinases that control HuR function, including protein kinase C (PKC) and the MAPK p38. Although less is known about their influence on HuR function after DNA damage, they are also expected to be intimately linked to this response ([Figure 1](#fig1){ref-type="fig"}).

5.1. PKC {#sec5.1}
--------

Protein kinase C (PKC)*α* was reported to phosphorylate HuR at S158 and S221 while PKC*δ* was phosphorylated HuR at S221 and S318 \[[@B61], [@B54], [@B62], [@B63]\]. PKC*α* and PKC*δ* were implicated in the cytoplasmic export of HuR, its enhanced association with target transcripts (e.g., *COX-2*, *cyclin D1*, and *cyclin A* mRNAs), and their stabilization \[[@B61], [@B54], [@B62], [@B63]\]. Doller and coworkers primarily examined the effect of angiotensin II (AngII) in human mesangial cells, uncovering a complex set of regulatory features. However, PKC is a *bona fide* DNA damage response kinase \[[@B64], [@B65]\]. The influence of PKC on HuR-modulated gene expression is a promising area for future study.

5.2. p38 {#sec5.2}
--------

The MAPK p38 plays a key role in the growth arrest that follows exposure to DNA-damaging agents \[[@B66]--[@B68]\]. An important mediator of this effect is the cdk inhibitor p21, whose levels increase in response to genotoxins such as IR. The Nebreda laboratory recently showed that following IR, p38 phosphorylated HuR at T118, leading to the cytoplasmic accumulation of HuR, and increased the binding of HuR to *p21* mRNA. *p21* mRNA was thus stabilized, leading to increased expression of p21 protein and to the activation of the G1/S checkpoint \[[@B69]\]. Inhibiting p38 or using the non-phosphorylatable mutant HuR(T118A) prevented the p38-mediated increase in p21 expression after IR, which abrogated the G1/S arrest. The effect of p38 upon HuR translocation and binding to target mRNAs appears to require the p38 downstream substrate MAPKAPK-2 (MK2), as shown in cells responding to taxanes or oxidants \[[@B71], [@B70]\], although MK2 does not appear to phosphorylate HuR directly. While a direct influence of p38 on HuR after H~2~O~2~ has not been studied to date, the mutant HuR(T118A) also showed reduced binding to *p21* mRNA in H~2~O~2~-treated cells \[[@B27]\], suggesting that H~2~O~2~-activated p38 could similarly change HuR binding to target mRNAs.

5.3. Additional Kinases Affecting HuR Function {#sec5.3}
----------------------------------------------

The AMP-activated protein kinase (AMPK) does not phosphorylate HuR directly, but it phosphorylates and enhances the acetylation of importin *α*1 \[[@B71]\]; in turn, importin *α*1 favors the nuclear import of HuR. Stress conditions that reduce AMPK activity can suppress this import pathway, thus allowing cytoplasmic HuR to accumulate \[[@B72]\]. How DNA damage affects importin 1*α*-mediated localization of HuR remains to be tested directly. Finally, an as-yet unidentified kinase was reported to phosphorylate HuR at S242, promoting its nuclear retention \[[@B73], [@B74]\] ([Figure 1](#fig1){ref-type="fig"}).

6. Concluding Remarks {#sec6}
=====================

HuR function is regulated by several kinases that play central roles in the DNA damage response, notably those in the ATM/ATR → Chk1/Chk2 pathway. Together with PKC and p38, these signaling cascades govern HuR\'s cytoplasmic abundance and interaction with target mRNAs. It is intriguing that these kinases converge on a shared substrate protein, HuR, which potently influences gene expression patterns posttranscriptionally. A deeper understanding of the signaling pathways that govern HuR function is helping to elucidate HuR\'s role in the overall DDR and in the gene expression changes that ensue.

The emergence of HuR a key effector of the DDR program has important biological and clinical implications. First, it suggests that modulation of gene expression by ATM/ATR → Chk1/Chk2 is strongly influenced by HuR; consequently, cells with impaired ATM/ATR → Chk1/Chk2 signaling could express different subsets of proteins due to aberrant HuR function (localization and RNA-binding activity). Second, since lowering HuR levels or preventing its phosphorylation reduced cell survival following genotoxic damage \[[@B26], [@B27], [@B75]\], HuR could be a promising target for therapeutic intervention. Third, the high levels of HuR observed in many cancers (which appear to underlie HuR\'s role in tumorigenesis \[[@B76], [@B77]\]) could engender an effective DDR in cancer cells. Thus, cancer treatments that do not rely on DNA damage might be advantageous when tumoral HuR levels are elevated.

In sum, the posttranscriptional control of gene expression is particularly important during the DDR, when transcription may be depressed to avoid the synthesis of aberrant transcripts. Through post-translational modification by the kinases reviewed here (primarily ATM/ATR → Chk1/Chk2, but also PKC and p38), HuR helps to orchestrate protein expression from pre-existing mRNAs following damage to DNA. In this capacity, HuR is a key factor that helps to ensure the maintenance of cellular homeostasis following genotoxic injury.
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![Sites of HuR phosphorylation by DNA damage-inducible kinases. Schematic of HuR depicting the RNA recognition motifs (RRMs, dark blue), the hinge region (brown) with the HuR nucleocytoplasmic shuttling sequence (HNS), the sites of phosphorylation (under "Phosphorylated Amino Acids"), and the DNA Damage-Regulated Kinases responsible, including an unknown kinase predicted to phosphorylate S242. The consequences of HuR phosphorylation at the different sites are indicated under "Impact on HuR Function". More details in the text.](JNA2010-981487.001){#fig1}

![Regulation of HuR function by ATM/ATR → Chk1/Chk2. ATM/ATR regulates HuR function through the activation of Chk1 and Chk2. Active Chk1 phosphorylates (and hence inactivates) Cdk1, a kinase that phosphorylates HuR at S202; in turn, unphosphorylated HuR(S202) can be transported to the cytoplasm (orange). Active Chk2 phosphorylates HuR at S88, S100, and T118 (at RRM1 and RRM2); in turn, HuR association with target mRNAs is altered (purple). Jointly, ATM/ATR → Chk1/Chk2 modulates the amount of HuR in the cytoplasm and its interaction with target mRNAs (green).](JNA2010-981487.002){#fig2}

###### 

HuR target mRNAs showing altered expression after DNA damage. Partial list of HuR target mRNAs encoding proteins that change following DNA damage (first column), the region of interaction with HuR (second column), and the genotoxic damage that was shown to affect HuR regulation of the mRNA (third column); "n.r.": no reported. The HuR kinases linked to the regulation of the mRNAs in the first column are indicated (fourth column).

                       Target mRNA after DNA damage   Binding region      DNA damage conditions affecting regulation by HuR   HuR Kinase           References
  -------------------- ------------------------------ ------------------- --------------------------------------------------- -------------------- ------------
  mRNA stabilization   *c-fos*                        3′UTR               n.r.                                                n.r.                 \[−\]
  *p21*                3′UTR                          UVC, arsenite, IR   Chk2, p38                                           \[[@B27], [@B64]\]   
  *cyclin A2*          3′UTR                          H~2~O~2~            Chk2, Cdk1                                          \[[@B27], [@B29]\]   
  *cyclin B1*          3′UTR                          H~2~O~2~            n.r.                                                \[[@B73]\]           
  *cyclin D1*          3′UTR                          UVC                 Chk2                                                \[[@B27]\]           
  *iNOS*               3′UTR                          n.r.                n.r.                                                \[−\]                
  *VEGF*               3′UTR                          n.r.                n.r.                                                \[−\]                
  *SIRT1*              3′UTR                          H~2~O~2~            Chk2                                                \[[@B27]\]           
  *TNF-α*              3′UTR                          n.r.                n.r.                                                \[−\]                
  *bcl-2*              3′UTR                          n.r.                Cdk1                                                \[[@B28]\]           
  *mcl-1*              3′UTR                          n.r.                Cdk1                                                \[[@B28]\]           
  *COX-2*              3′UTR                          n.r.                PKC, p38                                            \[[@B61], [@B71]\]   
  *uPA*                3′UTR                          n.r.                n.r.                                                \[−\]                
  *uPAR*               3′UTR                          n.r.                n.r.                                                \[−\]                
  *IL-3*               3′UTR                          n.r.                n.r.                                                \[−\]                
  *MKP-1*              3′UTR                          H~2~O~2~            Cdk1                                                \[[@B53]\]           
                                                                                                                                                   
  ↑ Translation        *p53*                          3′UTR               UVC                                                 n.r.                 \[−\]
  *ProTα*              3′UTR                          UVC                 Chk2, Cdk1                                          \[[@B29]\]           
  *cytochrome c*       3′UTR                          n.r.                Chk2                                                \[[@B27]\]           
  *MKP-1*              3′UTR                          H~2~O~2~            Cdk1                                                \[[@B29]\]           
  *HIF-1α*             3′UTR                          n.r.                Cdk1                                                \[[@B29]\]           
                                                                                                                                                   
  ↓  Translation       *p27*                          5′UTR               n.r.                                                n.r.                 \[−\]
  *IGF-IR*             5′UTR                          n.r.                n.r.                                                \[−\]                
  *Wnt5a*              3′UTR                          n.r.                n.r.                                                \[−\]                
  *HuR*                3′UTR                          n.r.                n.r.                                                \[−\]                
  *c-Myc*              3′UTR                          n.r.                n.r.                                                \[−\]                
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